FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046123570> ?p ?o ?g. }

• W3046123570 endingPage "e207911" @default.
• W3046123570 startingPage "e207911" @default.
• W3046123570 abstract "<h3>Importance</h3> Direct intratumoral delivery of immunotherapies is a compelling approach to overcoming barriers to systemic immunotherapy efficacy. While the use of intratumoral delivery of immunotherapy drugs is increasing rapidly in both the investigational and standard of care domains, the feasibility and safety of these interventions, particularly for deeper lesions that require image-guidance, remain unknown. <h3>Objective</h3> To address current knowledge gaps in image-guided techniques for intratumoral immunotherapy delivery and the safety of these interventions. <h3>Design, Setting, and Participants</h3> This case series study was performed at a single tertiary cancer center over a 2-year period from January 2016 to January 2018. Patients were followed until January 2019. All patients who underwent image-guided intratumoral delivery of immunotherapy agents in the standard of care, off-label, or investigational setting during the study period were included. Data were analyzed from February 1 to June 1, 2019. <h3>Exposures</h3> Image-guided biopsies and intratumoral injections of immunotherapies across several clinical trials as well as standard of care talimogene laherparepvec therapy. <h3>Main Outcomes and Measures</h3> Technical success, defined as the delivery of the prescribed injectate volume in its entirety, for image-guided biopsy and injections and procedure-related adverse events. <h3>Results</h3> A total of 85 patients (median [interquartile range] age, 61 [47-71] years; 42 [52%] men) underwent 498 encounters during the study period. These encounters comprised 327 image-guided intratumoral investigational agent injections in 67 patients in clinical trials, including 33 patients with melanoma (50%), 14 patients with sarcoma (21%), 3 patients with ovarian cancer (4.5%), 2 patients with breast cancer (3%), and 2 patients with colon cancer (3%). An additional 18 patients with melanoma underwent 113 image-guided talimogene laherparepvec injections. There were no adverse events reported related to the technical component of the procedure, specifically needle insertion or biopsy. Serious adverse events (Common Terminology Criteria for Adverse Events score ≥3), including dyspnea and severe flu-like symptoms developing within 24 hours of the injection and requiring hospitalization, occurred after 3 of 327 investigational agent injections (2%) and 4 of 113 talimogene laherparepvec injections (4%). <h3>Conclusions and Relevance</h3> The findings of this case series study suggest that intratumoral injections of immunotherapies were feasible across a range of histological conditions and target organs. Immediate postdelivery anticipated adverse events occurred in a small number of instances. Performing physicians should have the necessary safeguards in place to respond as needed. Optimal methods for intratumoral drug delivery remain unresolved, and efforts to standardize drug delivery techniques are required." @default.
• W3046123570 created "2020-08-03" @default.
• W3046123570 creator A5003827387 @default.
• W3046123570 creator A5015116006 @default.
• W3046123570 creator A5026095888 @default.
• W3046123570 creator A5030834372 @default.
• W3046123570 creator A5033798832 @default.
• W3046123570 creator A5034845901 @default.
• W3046123570 creator A5035218748 @default.
• W3046123570 creator A5069965459 @default.
• W3046123570 date "2020-07-29" @default.
• W3046123570 modified "2023-10-14" @default.
• W3046123570 title "Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer" @default.
• W3046123570 cites W1985148014 @default.
• W3046123570 cites W2079142824 @default.
• W3046123570 cites W2159966592 @default.
• W3046123570 cites W2473956396 @default.
• W3046123570 cites W2746176173 @default.
• W3046123570 cites W2749595412 @default.
• W3046123570 cites W2750781282 @default.
• W3046123570 cites W2897639828 @default.
• W3046123570 doi "https://doi.org/10.1001/jamanetworkopen.2020.7911" @default.
• W3046123570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32725245" @default.
• W3046123570 hasPublicationYear "2020" @default.
• W3046123570 type Work @default.
• W3046123570 sameAs 3046123570 @default.
• W3046123570 citedByCount "48" @default.
• W3046123570 countsByYear W30461235702020 @default.
• W3046123570 countsByYear W30461235702021 @default.
• W3046123570 countsByYear W30461235702022 @default.
• W3046123570 countsByYear W30461235702023 @default.
• W3046123570 crossrefType "journal-article" @default.
• W3046123570 hasAuthorship W3046123570A5003827387 @default.
• W3046123570 hasAuthorship W3046123570A5015116006 @default.
• W3046123570 hasAuthorship W3046123570A5026095888 @default.
• W3046123570 hasAuthorship W3046123570A5030834372 @default.
• W3046123570 hasAuthorship W3046123570A5033798832 @default.
• W3046123570 hasAuthorship W3046123570A5034845901 @default.
• W3046123570 hasAuthorship W3046123570A5035218748 @default.
• W3046123570 hasAuthorship W3046123570A5069965459 @default.
• W3046123570 hasBestOaLocation W30461235701 @default.
• W3046123570 hasConcept C119060515 @default.
• W3046123570 hasConcept C121608353 @default.
• W3046123570 hasConcept C126322002 @default.
• W3046123570 hasConcept C126838900 @default.
• W3046123570 hasConcept C141071460 @default.
• W3046123570 hasConcept C143998085 @default.
• W3046123570 hasConcept C2775934546 @default.
• W3046123570 hasConcept C2777701055 @default.
• W3046123570 hasConcept C535046627 @default.
• W3046123570 hasConcept C71924100 @default.
• W3046123570 hasConceptScore W3046123570C119060515 @default.
• W3046123570 hasConceptScore W3046123570C121608353 @default.
• W3046123570 hasConceptScore W3046123570C126322002 @default.
• W3046123570 hasConceptScore W3046123570C126838900 @default.
• W3046123570 hasConceptScore W3046123570C141071460 @default.
• W3046123570 hasConceptScore W3046123570C143998085 @default.
• W3046123570 hasConceptScore W3046123570C2775934546 @default.
• W3046123570 hasConceptScore W3046123570C2777701055 @default.
• W3046123570 hasConceptScore W3046123570C535046627 @default.
• W3046123570 hasConceptScore W3046123570C71924100 @default.
• W3046123570 hasIssue "7" @default.
• W3046123570 hasLocation W30461235701 @default.
• W3046123570 hasOpenAccess W3046123570 @default.
• W3046123570 hasPrimaryLocation W30461235701 @default.
• W3046123570 hasRelatedWork W2002120878 @default.
• W3046123570 hasRelatedWork W2003938723 @default.
• W3046123570 hasRelatedWork W2047967234 @default.
• W3046123570 hasRelatedWork W2061253854 @default.
• W3046123570 hasRelatedWork W2118496982 @default.
• W3046123570 hasRelatedWork W2135221496 @default.
• W3046123570 hasRelatedWork W2439875401 @default.
• W3046123570 hasRelatedWork W2946562078 @default.
• W3046123570 hasRelatedWork W4294943482 @default.
• W3046123570 hasRelatedWork W2525756941 @default.
• W3046123570 hasVolume "3" @default.
• W3046123570 isParatext "false" @default.
• W3046123570 isRetracted "false" @default.
• W3046123570 magId "3046123570" @default.
• W3046123570 workType "article" @default.